GLP-1RAs reduce glycemia in patients with T2DM by increasing glucose-induced insulin secretion and inhibiting glucagon secretion via the stimulation of pancreatic GLP‐1 receptors in beta and alpha cells and by increasing insulin sensitivity [5]. The gene discussed is INS; the disease is type 2 diabetes mellitus.